Interferon (IFN)-β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α. Differential effects on tumorigenicity and host response

American Journal of Pathology

Volumn 154, Issue 4, 1999, Pages 1211-1222

  Rozera, Carmela ^a   Carlei, Davide ^a   Lollini, Pier Luigi ^b   De Giovanni, Carla ^b   Musiani, Piero ^c   Carlo, Emma Di ^c   Belardelli, Filippo ^a   Ferrantini, Maria ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; BETA INTERFERON; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CLONING VECTOR; GENE EXPRESSION; GENE TRANSFER; INTERMETHOD COMPARISON; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 0032929390     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65373-4     Document Type: Article

References (53)

1. Hussein AM: The potential application of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest 1996, 14:343-352
2. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumor-cell death, and immunogenicity: a question of choice, Immunol Today 1997, 18:32-36
3. + T cell-mediated tumor rejection and development of antitumor immunity: comparative studies with IFN-γ producing TS/A cells. J Immunol 1994, 153:4604-4615
4. Tüting T, Gambotto A, Baar J, Storkus, WJ, Zavodny PJ, Narula S, Tahara H, Robbins PD, Lotze MT: Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther 1997, 4:1053-1060
5. 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993, 53:1107-1112
6. Kaido T, Bandu MT, Maury C, Ferrantini M, Belardelli F, Gresser I: IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995, 60:1-9
7. 1 transfected Friend leukemia cells. Am J Pathol 1995, 147:445-460
8. Sarkar S, Flores I, De Rosa C, Ozzello L, Ron Y, Pestka S: Injection of irradiated melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int J Oncol 1995, 7:17-24
9. Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH, deKernion JB: Human renal carcinoma line transfected with interleukin-2 and/or interferon α gene(s): implications for live cancer vaccines. J Natl Cancer Inst 1993, 85:207-216
10. Zhang JF, Hu C, Geng Y, Blatt LM, Taylor, MW: Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression Cancer Gene Ther 1996, 3:31-38
11. Dong Z, Juang SH, Kumar R, Eue I, Xie K, Bielenberg D, Lu W, Bucana C, Yang X, Fidler I: Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-β gene. Cancer Immunol Immunother 1998, 46:137-146
12. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J: Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998, 95:14411-14416
13. Nanni P, De Giovanni C, Lollini PL, Nicoletti G, Prodi G: TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983, 1:373-380
14. Lollini PL, Bosco MC, Cavallo F, De Giovanni C, Giovarelli M, Landuzzi L, Musiani P, Modesti A, Nicoletti G, Palmieri G, Santoni A, Young HA, Forni G, Nanni P: Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene. Int J Cancer 1993, 55:320-329
15. Belardelli F, Gresser I, Maury C, Maunoury MT: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. Int J Cancer 1982, 30:813-820
16. Markowitz D, Goff S, Bank A: A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988, 62: 1120-1124
17. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988, 167:400-406
18. Belardelli F, Gessani S, Proietti E, Locardi C, Borghi P, Watanabe Y, Kawade Y, Gresser I: Studies on the expression of spontaneous and induced interferons in mouse peritoneal macrophages by means of monoclonal antibodies to mouse interferons. J Gen Virol 1987, 68: 2203-2212
19. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. BioTechniques 1989, 7:980-984
20. De Giovanni C, Palmieri G, Nicoletti G, Landuzzi L, Scotlandi K, Bontadini A, Tazzari PL, Sensi M, Santoni A, Nanni P, Lollini PL: Immunological and nonimmunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. Int J Cancer 1991, 48:270-276
21. Gutterman JU: Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci USA 1994, 91:1198-2005
22. Belardelli F, Gresser I: The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996, 17:369-372
23. Tahara H, Kamada K, Sato E, Tsuyama N, Kim JK, Hara E, Oda K, Ide T: Increase in expression levels of interferon-inducible genes in senescent human diploid fibroblasts and in SV40-transformed human fibroblasts with extended lifespan. Oncogene 1995, 11:1125-1132
24. Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, Tsujiya H, Tsukamoto T: In vitro comparative study of the antitumor effects of human interferon-α, β, and γ on the growth and invasive potential of human melanoma cells. J Dermatol 1995, 22:631-636
25. Garbe C, Krasagakis K: Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993, 100(Suppl 2):239S-244S
26. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW: Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 1992, 84:1185-1190
27. Rosenblum MG, Yung WK, Kelleher PJ, Ruzicka F, Steck PA, Borden EC: Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: correlation of receptor binding, 2′,5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 1990, 10:141-151
28. Hubbell HR, Liu RS, Maxwell BL: Independent sensitivity of human tumor cell lines to interferon and double-stranded RNA. Cancer Res 1984, 44:3252-3257
29. Willson JK, Bittner G, Borden EC: Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay. J Interferon Res 1984, 4:441-447
30. De Marco F, Giannoni F, Marcante ML Interferon-β strong cytopathic effect on human papillomavirus type 16-immortalized HPK-IA cell line, unexpectedly not shared by interferon-α. J Gen Virol 1995, 76:445-450
31. De Marco F, Marcante ML: Cellular and molecular analyses of interferon β cytopathic effect on HPV-16 in vitro transformed human keratinocytes (HPK-IA). J Biol Omeost Agents 1995, 9:24-30
32. Rani MRS, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM: Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α. J Biol Chem 1996, 271:22878-22884
33. Platanias LC, Uddin S, Colamonici OR: Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. Interferon-β selectively induces tyrosine phosphorylation of an α subunit-associated protein. J Biol Chem 1994, 269:17761-17764
34. Miscia S, Baldassarre AD, Rana RA, Cataldi A: Phospholipase C γ 1 overexpression and activation induced by interferon β in human T lymphocytes: an ISGF3-independent response. Cytokine 1997, 9:660-665
35. L subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNα2 and IFNβ. J Biol Chem 1998, 273:3144-3147
36. Soilu-Hanninen M, Salmi A, Salonen R: Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995, 60:99-106
37. Pette M, Pette DF, Muraro PA, Farnon E, Martin R, McFarland HF: Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 1997, 49:385-392
38. Gene K, Dona DL, Reder AT: Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J Clin Invest 1997, 99:2664-2671
39. McRae BL, Picker LJ, van Seventer GA: Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur J Immunol 1997, 27:2650-2656
40. Fabra A, Nakajima M, Bucana CD, Fidler IJ: Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 1992, 52:101-110
41. Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T, Nakajima M: Human recombinant interferons-β and -γ decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 1994, 58:380-384
42. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92:4562-4566
43. Kato N, Nawa A, Tamakoshi K, Kikkawa F, Suganuma N, Okamoto T, Goto S, Tomoda Y, Hamaguchi M, Nakajima M: Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon β. Am J Obstet Gynecol 1995, 172.601-606
44. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, Ito Y, Onto M: Resolution of acute hepatitis C after therapy with natural β interferon. Lancet 1991, 338:914-915
45. Dinsmore W, Jordan J, O'Mahony C, Harris JR, McMillan A, Radcliffe KW, Engrand P, Jackson BW, Galazka AR, Abdul-Ahad AK, Illingworth JM: Recombinant human interferon-β in the treatment of condylomata acuminata. Int J STD AIDS 1997, 8:622-628
46. Hall GL, Compston A, Scolding NJ: Beta-interferon and multiple sclerosis. Trends Neurosci 1997, 20:63-67
47. Dvorak HF, Gresser I: Microvascular injury in pathogenesis of IFN-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989, 81:497-502
48. Thomas H, Balkwill FR: Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 1991, 52:307-330
49. Ezekowitz RAB, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326: 1456-1463
50. Volm MD, von Roenn JH: Treatment strategies for epidemic Kaposi's sarcoma. Curr Opin Oncol 1995, 7:429-436
51. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987, 47:5155-5161
52. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ: Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994, 145:365-374
53. Bocci V: Distribution, catabolism, and pharmacokinetics of interferons. Interferon: In Vivo and Clinical Studies, vol 4. Edited by Finter NB, Oldham RK. Amsterdam, Elsevier Science Publishers, 1985, pp 47-72